Baird Downgrades Applied Therapeutics to Neutral with Price Target Cut to 25 Cents
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Baird analyst Brian Skorney downgraded Applied Therapeutics to Neutral from Outperform with a price target of 25c, down from $2, after Applied agreed to be acquired by Cycle Group for 8.8c per share in cash payable at closing plus one non-transferrable contingent value right that entitles the holder to receive potential additional payments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
